Full Breakdown
Federal Appeals Court Reviews Louisiana Challenge to Mail-Order Abortion Drug Policy
9/10/2026, 10:01:35 AM
Core Legal Battle Over Mail-Order Mifepristone
A three-judge panel of the Fifth Circuit Court of Appeals convened for oral arguments on Louisiana’s effort to block the federal policy that permits abortion medication mifepristone to be shipped and taken remotely. The state’s attorneys contend that the Food and Drug Administration (FDA) lacked sufficient safety data before rescinding the in-person dispensing requirement, and they argue that the policy change is “arbitrary and capricious.” The hearing focused on whether Louisiana has standing to sue and whether the policy causes tangible harm to the state.
Background: FDA Policy Shift and State Authority
In 2023 the Biden administration removed an FDA safeguard that required a patient to receive mifepristone in person, allowing the drug to be mailed to patients nationwide. The change came after the Supreme Court’s 2022 decision overturning *Roe v. Wade*, which restored authority to the states to regulate abortion. Louisiana’s challenge therefore rests on the premise that, post-*Roe*, states may set their own abortion-related rules, including restrictions on medication abortion.
Official Positions and Arguments
- Louisiana Solicitor General J. Benjamin Aguinaga argued that the FDA’s rule-making process did not include adequate evidence of safety and that the agency’s reversal of the in-person requirement introduced additional risk to a medication already considered risky.
- Jessica Ellsworth, representing Danco Laboratories—the manufacturer of mifepristone—maintained that the state’s petition should be denied, emphasizing that the Supreme Court had already granted a stay of the lower-court injunction, thereby keeping the Biden-era policy in effect while litigation proceeds.
- The FDA petitioned the Supreme Court for a stay of the Fifth Circuit’s May injunction; the high court granted the stay about two weeks later, preserving the mail-order rule during the ongoing appeal.
Potential Impact and Stakes
If the appeals court ultimately rules in favor of Louisiana, the decision could reinstate in-person dispensing requirements nationwide, limiting remote access to medication abortion and setting a precedent for other states to challenge federal drug-distribution policies. Conversely, upholding the FDA’s rule would reinforce the agency’s authority to modify drug-access regulations without state interference, shaping the landscape of reproductive health services across the United States.
